按治療類型、藥物類別、最終用戶、通路、給藥途徑、患者年齡層和PFIC類型分類的進行性遺傳性肝內膽汁淤積症治療市場 - 全球預測 2025-2032

預計到 2032 年，進行性遺傳性肝內膽汁淤積症治療市場將成長至 1.7,281 億美元，複合年成長率為 4.81%。

關鍵市場統計數據
基準年 2024	1.1862億美元
預計年份：2025年	1.244億美元
預測年份 2032	1.7281億美元
複合年成長率 (%)	4.81%

本書對進行性家族性肝內膽汁淤積症（PFIC）的臨床、治療和運作方面進行了簡明扼要、權威的概述，並闡明了各相關人員的戰略重點。

進行性遺傳性肝內膽汁淤積症 (PFIC) 是一種遺傳和臨床表現異質性很強的膽汁淤積性肝病，在診斷、臨床管理和長期照護方面都面臨著許多挑戰。患者自幼年起便出現進行進行性肝功能障礙，通常需要藥物、支持性治療、手術等多種方法的綜合治療。因此，臨床醫生、研究人員和醫療保健系統都在尋求多管齊下的策略，力求在短期控制症狀的同時，透過持續干預來改變疾病的生物機制。

本執行摘要組裝了目前進行性家族性肝內膽汁淤積症 (PFIC) 治療的格局，綜合分析了各種治療方法、監管路徑和治療模式的最新進展。摘要重點闡述了重塑臨床優先事項的促進因素，包括旨在降低肝內膽汁酸負荷的新型標靶藥物、不斷發展的肝移植和肝再形成手術標準，以及專科醫療網路的日益成熟。此外，摘要還強調了將臨床創新與供應鏈韌性、支付方參與和以患者為中心的醫療模式相結合的重要性，以確保先進療法能夠帶來公平的實際益處。在此背景下，引言部分為讀者深入探討變革性轉變、細分資訊、區域洞察以及針對整個治療生態系統相關人員的戰術性建議做好了準備。

新的治療創新、適應性監管方法和整合式照護模式正在融合，重新定義進行性家族性肝內膽汁淤積症（PFIC）的治療範式和應用路徑。

近年來，科學、監管和醫療服務等多面向因素的共同作用，為進行性家族性肝內膽汁淤積症（PFIC）的治療格局帶來了變革性變化。分子遺傳學的進步和對膽汁酸生理學更深入的理解，加速了標靶藥物療法的研發，這些療法能夠直接調節腸肝膽汁酸循環。這項發展使得治療選擇不再局限於針對症狀的支持性治療，而是擴展到能夠改變疾病進程、延緩甚至避免侵入性手術介入的藥物。

同時，臨床實踐正開始採用更一體化的醫療模式，將肝病專科中心、協調的營養支持以及早期轉診途徑納入移植評估。監管機構正在提供適應性路徑和孤兒藥獎勵，以加速罕見疾病治療方法的研發。診斷技術的進步、標靶藥物研發管線的不斷擴充以及健保報銷機制的演變，共同推動著策略重點的轉變。申辦方現在必須制定差異化的臨床方案、為支付者提供清晰的實證策略，並與專科診所和移植中心夥伴關係，以支持病患監測。

評估美國計劃於 2025 年徵收的關稅將如何影響 PFIC 療法的供應鏈、臨床項目、採購和患者獲取途徑。

美國近期宣布的將於2025年生效的關稅，透過影響跨境供應鏈的經濟和物流，為被動外國干預性免疫缺陷（PFIC）治療生態系統增添了新的複雜性。許多專科藥物、原料和生物製藥都依賴國際生產和分銷網路。如果關稅導致活性原料藥、最終產品和輔助器具的境內價格上漲，申辦方和經銷商將面臨壓力，必須重新評估其籌資策略、庫存管理以及與生產合作夥伴的合約條款。

這些成本壓力也將波及醫院、專科診所和藥局管道的採購慣例，迫使它們加強與生產商的談判，並更嚴格地評估處方發放情況。臨床開發項目也將受到影響。臨床實驗藥物的供應預算、進出口計劃以及臨床實驗試驗地點的選擇可能需要進行調整，以確保臨床實驗藥物供應的連續性。為此，相關人員正在優先考慮供應鏈多元化、盡可能將關鍵生產流程外包到近岸地區，並加強需求預測，以減輕關稅波動的影響。支付者的參與策略同樣必須納入採購成本上升的影響，重點在於強調減少後續住院和移植需求的衛生經濟學論點。總而言之，關稅環境凸顯了製定策略規劃的必要性，以最大限度地減少中斷，同時確保患者能夠及時獲得必要的PFIC治療。

整合細分情報，揭示治療類型、藥物類別、治療環境、管道、給藥途徑、年齡層和PFIC亞型如何影響策略和執行。

在進行局部膽汁淤積症 (PFIC) 的治療過程中，由於涉及不同的治療層級、護理環境和患者群體，因此，以細分市場為導向的決策對於客製化開發和商業化至關重要。就治療類型而言，藥物治療是緩解疾病和症狀控制的主要臨床策略，其中膽汁酸抑制劑和髂骨膽汁酸轉運體抑制劑是重點標靶機制。在藥物治療中，膽汁酸抑制劑（例如考來烯胺和考來維崙）在改善症狀和生化指標方面發揮作用，而迴腸膽汁酸轉運體抑制劑（例如馬拉利西巴和奧德維西巴）旨在減少有害膽汁酸的積累。利福平和熊去氧膽酸等輔助治療藥物在緩解症狀和改善生化指標方面也發揮作用。對於難治性或進行性疾病，外科手術（從膽道改道到肝臟移植）則是升級治療途徑。

在藥物類別中，區分抗生素、螯合劑、IBAT抑制劑和膽汁酸調變器有助於進一步細化優先排序，因為它們會影響臨床試驗終點、安全性監測和商業化方案。終端使用者細分突顯了不同的需求，例如居家醫療機構、醫院住院服務和專科診所網路，這些都需要客製化的分銷、教育和依從性支援。分銷管道的選擇，包括醫院藥房、線上藥房和零售藥房，決定了治療藥物如何到達患者以及如何管理供應保障。給藥途徑區分了口服和靜脈注射產品，並影響依從性策略和臨床支持的需求。兒科、青少年和成人年齡層需要適合其年齡的製劑和給藥策略，而PFIC亞型（I型、II型和III型）的分類則決定了分子標靶策略、臨床試驗納入標準和長期療效預期。整合這些部分可以更準確地識別患者、設計臨床路徑，並制定針對 PFIC 治療複雜現實的上市策略。

美洲、歐洲、中東和非洲以及亞太地區在臨床網路、支付方框架和醫療保健基礎設施方面的區域差異，決定了醫療服務的可近性和普及性。

PFIC治療方案的研發、應用和報銷深受區域動態的影響，美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式和治療途徑有顯著差異。在美洲，卓越的醫療中心、完善的移植網路和成熟的專科藥房管道支持新型治療方法的早期應用，但支付方越來越需要可靠的真實世界證據和長期療效數據來證明高成本治療方法的合理性。在此背景下，能夠證明患者獲益顯著並建構包含移植項目和兒科肝病中心在內的綜合治療路徑的申辦方將更具優勢。

中東和非洲地區法律規範分散，報銷機制各異，因此需要不同的市場進入策略。設有集中式衛生技術評估機構的國家專注於衛生經濟模型和療效比較證據，而其他地區則可能利用管理式准入協議來實現患者早期獲得治療。專科診所和醫院系統在協調護理和提供複雜干預措施方面發揮著至關重要的作用。在亞太全部區域，醫療基礎設施的多樣性、移植機會的差異以及不同的監管預期，都要求制定靈活的臨床和商業計劃。一些市場正透過擴大罕見疾病計畫來加速推廣應用，而有些市場則優先考慮診斷和專科護理能力的建設。總而言之，區域策略必須考慮臨床網路成熟度、支付方預期、供應物流和專科藥局管道等方面的差異，才能確保PFIC患者獲得有效且公平的治療。

創新者、專業製造商和臨床網路如何協調研發、夥伴關係和營運策略，以塑造PFICs領域的競爭地位和招募工作

在PFIC（原發性家族性發炎性疾病）領域，公司層面的動態變化將專業化、策略夥伴關係和適應性商業化策略結合，作為其競爭地位的關鍵要素。開發標靶藥物的創新企業通常與臨床中心和學術網路合作，設計能夠捕捉重要終點的試驗，例如減輕搔癢、改善生化指標或實現無移植生存。專業製藥和生物製藥開發商透過製劑科學、兒科友善給藥途徑以及面向監管機構和支付方的數據生成計劃來脫穎而出。同時，醫療服務提供者和移植中心作為策略合作夥伴的角色日益凸顯，他們支持建立註冊登記系統、追蹤長期療效以及推動新型治療方法的協作式照護路徑。

製造商、合約研究與受託製造廠商以及專業經銷商之間的合作對於維持特定療法的持續供應至關重要。能夠實現共用生產能力、區域分銷中心和整合患者支援服務的策略聯盟，可以縮短患者用藥時間並降低供應中斷的風險。投資於強力的核准後證據生成（例如自然史研究和真實世界註冊研究）的公司，能夠向支付方建立更強大的價值提案。最後，將臨床差異化與可驗證的營運能力（例如病患支援計畫和臨床醫生教育計畫）相結合的競爭策略，往往能夠加速產品推廣，並鞏固其在PFIC治療領域的長期地位。

領導者可以採取實際有效的行動，協調證據產生、供應鏈韌性和商業策略，以加速PFIC的推廣應用並改善患者預後。

產業領導者必須採取一系列協調一致的行動，以確保PFIC的科學進展能夠轉化為持續的臨床和商業性影響。首先，研發項目應優先考慮能夠反映患者真實體驗和長期器官保存情況的終點指標，並使研究設計與支付方的證據需求保持一致。申辦方還應儘早投資於真實世界證據平台和病患登記系統，以連接臨床試驗數據和長期療效，並支持醫保報銷談判和核准後監測。

同時，與專科藥房和居家照護機構建立策略夥伴關係將有助於患者更可靠地獲得所需藥物。商業策略應針對每個終端使用者進行細緻調整，包括為醫院和專科診所提供教育項目，為居家照護患者提供用藥依從性和支持，以及為零售藥房和線上藥房管道簡化獲取途徑。此外，優先開發適合兒童的配方和給藥途徑將有助於促進不同年齡層的更廣泛應用。最後，加強與移植中心和多學科護理團隊的密切合作，有助於確保升級治療方案切實有效，並將新治療方法整合到能夠改善患者生活品質和長期療效的綜合護理計劃中。

結合主要相關人員訪談、臨床文獻綜合和情境分析的嚴謹混合方法，將檢驗對PFIC相關人員具有實際意義的見解。

本研究綜合分析採用多方法，旨在整合臨床專業知識、相關人員的觀點以及同儕審查文獻中的證據。主要研究包括對臨床醫生、移植外科醫生、專科藥劑師和支付方代表進行結構化訪談，以了解治療選擇、供應物流和報銷方面的實際考慮。這些質性資訊與近期臨床文獻的系統性回顧進行交叉比對，以識別PFIC試驗中使用的新型治療機制、相關安全性考量和研究終點。

透過分析醫院、專科診所和居家照護機構的配送實務和護理服務模式，以及考慮影響依從性和患者體驗的製劑和給藥途徑限制因素，我們獲得了營運和商業方面的見解。我們透過情境分析評估了供應鏈的影響，該分析考慮了關稅、跨境生產依賴性以及諸如近岸外包和冗餘採購等緩解措施的影響。在整個過程中，我們透過與關鍵意見領袖和臨床專案經理的後續諮詢來檢驗所獲得的洞見，以確保建議切實可行、符合臨床規範，並符合現行法規和支付方的期望。此調查方法優先考慮嚴謹性、相關人員相關性以及對實際決策的適用性。

一份策略性綜合報告，重點闡述了將治療創新轉化為持續改善進行性家族性肝內膽汁淤積症（PFIC）患者預後所需的條件和協作行動。

受科學進步、醫療模式演變和經濟限制變化的影響，進行性家族性肝內膽汁淤積症（PFIC）的治療格局正處於曲折點。靶向調節膽汁酸代謝的藥物療法、完善的多學科診療網路以及適應性監管路徑，共同為改善進行性膽汁淤積性肝病患者的預後創造了機會。然而，要實現這些益處，需要各方協同努力：一方面，需要提供強力的證據以說服監管機構和支付方；另一方面，需要製定能夠降低外部風險的供應鏈策略；此外，還需要製定能夠反映終端用戶需求和當地醫療體系特點的商業化計劃。

將臨床開發與實際營運準備和以支付方為中心的價值論證相結合的相關人員，將更有能力把治療潛力轉化為可衡量的患者獲益。同樣重要的是，要與製造商、專科診所、移植中心和患者權益倡導網路建立夥伴關係，以確保公平且永續的治療途徑。透過這些要素的共同努力，可以推動PFIC患者的早期療育、降低發病率並改善長期預後。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• odevixibat 的 III 期臨床試驗數據顯示，該藥物可顯著減輕進行性家族性肝內膽汁淤積症 (PFIC) 患者的搔癢症狀並改善膽汁酸譜。
• 針對ABCB11突變的腺結合病毒基因療法的開發，旨在持續恢復PFIC 2型患者的膽汁分泌
• FXR促效劑研發管線在奧貝膽酸之外取得進展，以增強兒童進行性家族性肝內膽汁淤積症患者的膽汁淤積控制
• 將液態切片生物標記整合到PFIC臨床實踐中，用於早期檢測和疾病進展監測。
• 對新型PFIC療法進行成本效益分析，重點在於長期醫療資源利用與預算影響
• 一項真實世界證據研究評估了接受髂骨膽汁酸轉運抑制劑治療的PFIC患者的生活品質改善和依從性模式
• 利用數位健康平台建立的協作註冊庫將規範罕見疾病臨床試驗的表現型分析，並加速病患招募。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療類型分類的進行性遺傳性肝內膽汁淤積症治療市場

• 藥物治療
  • 抗生素
  • 膽汁酸分泌
    • 考來烯胺
    • 科爾塞維魯姆
  • IVAT抑制劑
    • 馬拉利希巴特
    • 奧德維西巴特
  • 利福平
  • 熊去氧膽酸
• 支持性護理
  • 營養支持
  • 症狀管理
• 手術介入
  • 膽道改道
  • 肝臟移植

第9章 依藥物類別分類的進行性遺傳性肝內膽汁淤積症治療市場

• 抗生素
• 膽汁酸分泌抑制劑
  • 考來烯胺
  • 科爾特維倫
• Ivat抑制劑
  • 馬拉利希巴特
  • 奧德維西巴特
• 熊去氧膽酸

第10章 依最終使用者分類的進行性遺傳性肝內膽汁淤積症治療市場

• 居家照護
• 醫院
• 專科診所

第11章 依通路分類的進行性遺傳性肝內膽汁淤積症治療市場

• 醫院藥房
• 網路藥房
• 零售藥房

第12章 依給藥途徑分類的進行性遺傳性肝內膽汁淤積症治療市場

• 靜脈注射
• 口服

第13章 依病患年齡層別分類的進行性遺傳性肝內膽汁淤積症治療市場

• 青春期
• 成人
• 孩子們

第14章 依類型分類的進行性遺傳性肝內膽汁淤積症治療市場

• I型
• II 型
• III型

第15章 各地區進行性遺傳性肝內膽汁淤積症治療市場

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第16章 依組別分類的進行性遺傳性肝內膽汁淤積症治療市場

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第17章 各國進行性遺傳性肝內膽汁淤積症治療市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第18章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • Albireo Pharma, Inc.
  • Mirum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Glenmark Pharmaceuticals Limited

The Progressive Familial Intrahepatic Cholestasis Treatment Market is projected to grow by USD 172.81 million at a CAGR of 4.81% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 118.62 million
Estimated Year [2025]	USD 124.40 million
Forecast Year [2032]	USD 172.81 million
CAGR (%)	4.81%

A concise and authoritative overview of the clinical, therapeutic, and operational context for PFIC care that frames strategic priorities across stakeholders

Progressive familial intrahepatic cholestasis (PFIC) represents a set of genetically and clinically heterogeneous cholestatic liver disorders that present complex challenges across diagnosis, clinical management, and long-term care. Patients encounter progressive liver dysfunction from early life onward, often requiring a mix of pharmacologic approaches, supportive interventions, and in many cases surgical procedures. Clinicians, researchers, and health systems are therefore pursuing multimodal strategies that balance immediate symptom control with durable approaches that alter disease biology.

This executive summary frames the contemporary landscape for PFIC treatment by synthesizing developments across therapeutic modalities, regulatory pathways, and care delivery models. It highlights the drivers reshaping clinical priorities, such as new targeted agents designed to reduce intrahepatic bile acid burden, evolving standards for liver transplantation and diversion procedures, and the maturation of specialist care networks. The narrative also emphasizes the importance of aligning clinical innovation with supply chain resilience, payer engagement, and patient-centered care models to ensure that advanced therapies translate into equitable real-world benefit. By setting this context, the introduction prepares the reader for a deeper exploration of transformative shifts, segmentation intelligence, regional considerations, and tactical recommendations aimed at stakeholders across the therapeutic ecosystem.

Emerging therapeutic innovations, adaptive regulatory approaches, and integrated care models converging to redefine treatment paradigms and adoption pathways for PFIC

Over the last several years, a confluence of scientific, regulatory, and care-delivery forces has produced transformative shifts in the PFIC landscape. Advances in molecular genetics and a deeper understanding of bile acid physiology have accelerated the development of targeted pharmacotherapies that directly modulate enterohepatic bile acid circulation. This evolution has expanded options beyond symptom-directed supportive care toward agents that may alter disease trajectory and delay or obviate the need for invasive surgical interventions.

At the same time, clinical practice has begun to embrace more integrated care models that combine specialized hepatology centers, coordinated nutritional support, and earlier referral pathways for transplant evaluation. Regulatory authorities have increasingly offered adaptive pathways and orphan-drug incentives that shorten timelines for therapies addressing ultra-rare diseases, while payers and health systems are refining value frameworks to assess long-term benefits versus upfront costs. The combination of improved diagnostics, a growing pipeline of targeted agents, and evolving reimbursement dialogues has shifted strategic imperatives: sponsors must now plan for differentiated clinical programs, a clear evidence generation strategy for payers, and partnerships with specialty clinics and transplant centers to support adoption and patient monitoring.

Evaluating how United States tariff measures slated for 2025 are poised to affect supply chains, clinical programs, procurement, and patient access for PFIC therapies

Recent tariff actions announced for 2025 within the United States create a new layer of complexity for the PFIC therapeutic ecosystem by affecting the economics and logistics of cross-border supply chains. Many specialized medicines, raw materials, and biologic components rely on international manufacturing and distribution networks. When tariffs increase the landed cost of active pharmaceutical ingredients, finished products, or ancillary devices, sponsors and distributors face pressure to reassess sourcing strategies, inventory practices, and contractual terms with manufacturing partners.

These cost pressures can ripple through procurement practices among hospitals, specialty clinics, and pharmacy channels, compelling tighter negotiations with manufacturers and more stringent evaluation of formulary placements. Clinical development programs are also affected: trial supply budgets, import/export timelines, and site selection may need realignment to maintain continuity of investigational product delivery. In response, stakeholders are prioritizing supply-chain diversification, near-shoring of critical manufacturing steps where feasible, and enhanced demand forecasting to reduce exposure to tariff volatility. Payer engagement strategies must similarly incorporate the implications of higher acquisition costs, focusing on health economic arguments that emphasize downstream reductions in hospitalization or transplantation needs. Overall, the tariff environment underscores the need for strategic planning that minimizes disruption while preserving timely patient access to essential PFIC therapies.

Integrated segmentation intelligence revealing how treatment types, drug classes, care settings, channels, routes, age cohorts, and PFIC subtypes shape strategy and execution

Segment-driven decisioning is essential for tailored development and commercialization in PFIC because the therapeutic journey spans distinct treatment classes, care settings, and patient cohorts. When considering treatment type, pharmacotherapy dominates clinical strategy for disease modification and symptom control, with topical emphasis on bile acid sequestrants and inhibitors of the ileal bile acid transporter as targeted mechanisms. Within pharmacotherapy, bile acid sequestrants such as cholestyramine and colesevelam serve symptomatic and biochemical roles, while IBAT inhibitors-represented by agents like maralixibat and odevixibat-are designed to reduce toxic bile acid accumulation. Complementary options such as rifampicin and ursodeoxycholic acid retain roles in symptom mitigation and biochemical improvement. Supportive care remains foundational, with nutritional support and symptom management critical to maintaining growth and quality of life, while surgical interventions ranging from biliary diversion procedures to liver transplantation provide escalation pathways for refractory or progressive disease.

Drug-class considerations further refine prioritization, with distinctions between antibiotics, sequestrants, IBAT inhibitors, and bile acid modulators influencing clinical trial endpoints, safety monitoring, and commercialization narratives. End-user segmentation highlights the differing needs of homecare environments, hospital inpatient services, and specialty clinic networks, each requiring tailored distribution, education, and adherence support. Distribution-channel choices-including hospital pharmacies, online dispensaries, and retail pharmacies-determine how therapies reach patients and how supply assurance must be managed. Route of administration differentiates products that are oral from those requiring intravenous delivery, shaping adherence strategies and clinical support requirements. Age-group segmentation across children, adolescents, and adults mandates age-appropriate formulations and dosing strategies, while PFIC subtype distinctions among Type I, Type II, and Type III drive molecularly targeted approaches, trial inclusion criteria, and long-term outcome expectations. Synthesizing these segments enables more precise patient identification, clinical pathway design, and go-to-market strategies tailored to the complex realities of PFIC care.

Regional differences in clinical networks, payer frameworks, and healthcare infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and adoption dynamics

Regional dynamics significantly influence how PFIC therapies are developed, adopted, and reimbursed, with important distinctions across the Americas, Europe Middle East & Africa, and Asia-Pacific that affect clinical practice patterns and access pathways. In the Americas, concentrated centers of excellence, established transplantation networks, and mature specialty pharmacy channels support early adoption of novel therapies, yet payers increasingly demand robust real-world evidence and longitudinal outcomes to justify coverage for high-cost interventions. This environment favors sponsors that can demonstrate clear patient-level benefits and create integrated care pathways involving transplant programs and pediatric hepatology centers.

In Europe Middle East & Africa, fragmented regulatory frameworks and variable reimbursement landscapes require differentiated market access approaches. Nations with centralized health technology assessment bodies emphasize health-economic modeling and comparative-effectiveness evidence, while other jurisdictions may leverage managed access agreements to enable early patient access. Specialty clinics and hospital systems play a vital role in coordinating care and delivering complex interventions. Across the Asia-Pacific region, heterogeneity in healthcare infrastructure, variable access to transplantation, and differing regulatory expectations necessitate flexible clinical and commercial plans. Some markets are accelerating adoption through expanded orphan-disease programs, while others prioritize capacity-building for diagnosis and specialist care. Taken together, regional strategies must account for differences in clinical networks, payer expectations, supply logistics, and the relative maturity of specialty pharmacy channels to achieve effective and equitable access for PFIC patients.

How innovators, specialty manufacturers, and clinical networks are aligning R&D, partnerships, and operational strategies to shape competitive positioning and adoption in PFIC

Company-level dynamics in PFIC combine specialization, strategic partnerships, and adaptive commercialization strategies as essential elements of competitive positioning. Innovators developing targeted agents often partner with clinical centers and academic networks to design trials that capture meaningful endpoints such as pruritus reduction, biochemical improvement, and transplantation-free survival. Specialty pharmaceutical firms and biologic developers differentiate through formulation science, pediatric-friendly administration routes, and data generation plans that address both regulators and payers. Meanwhile, providers and transplant centers increasingly act as strategic partners, supporting registry development, long-term outcome tracking, and coordinated care pathways that facilitate adoption of novel therapies.

Collaborations between manufacturers, contract development and manufacturing organizations, and specialty distributors are also central to maintaining supply continuity for niche therapeutic products. Strategic alliances that enable shared manufacturing capacity, regional distribution hubs, and integrated patient support services reduce time-to-patient and mitigate risks from supply disruptions. Companies that invest in robust post-approval evidence generation-including natural history studies and real-world registries-build stronger value propositions for payers. Finally, competitive strategies that combine clinical differentiation with demonstrable operational readiness, such as patient support programs and clinician education initiatives, tend to accelerate uptake and reinforce long-term position in the PFIC therapeutic space.

Practical, high-impact actions for leaders to align evidence generation, supply resilience, and commercial strategies to accelerate adoption and improve patient outcomes in PFIC

Industry leaders must adopt a coordinated set of actions to ensure that scientific advances in PFIC translate into sustained clinical and commercial impact. First, development programs should prioritize endpoints that reflect meaningful patient experiences and long-term organ preservation, aligning trial designs with payer evidence needs. Sponsors should also invest early in real-world evidence platforms and patient registries that can bridge clinical trial data to long-term outcomes, supporting reimbursement negotiations and post-authorization monitoring.

Operationally, diversifying manufacturing and distribution arrangements will reduce exposure to tariff-induced price pressures and logistical delays, while strategic partnerships with specialty pharmacies and homecare providers will enable more reliable patient access. Commercial strategies must be nuanced for different end users, with tailored educational programs for hospitals and specialty clinics, adherence and support offerings for homecare patients, and streamlined access pathways for retail and online pharmacy channels. Additionally, prioritizing pediatric-friendly formulations and administration routes will support broader adoption across age cohorts. Lastly, fostering closer collaboration with transplant centers and multidisciplinary care teams will ensure that escalation pathways remain fit-for-purpose and that new therapies are integrated into comprehensive care plans that improve patient quality of life and long-term outcomes.

A rigorous mixed-methods approach combining primary stakeholder interviews, clinical literature synthesis, and scenario analysis to validate actionable insights for PFIC stakeholders

This research synthesis is grounded in a multi-method approach designed to integrate clinical expertise, stakeholder perspectives, and evidence from peer-reviewed literature. Primary research included structured interviews with clinicians, transplant surgeons, specialty pharmacists, and payer representatives to capture practical considerations around treatment selection, supply logistics, and reimbursement. These qualitative inputs were triangulated with systematic review of recent clinical literature to identify emerging therapeutic mechanisms, relevant safety considerations, and trial endpoints used in PFIC studies.

Operational and commercial insights were informed by analysis of distribution practices and care-delivery models across hospital, specialty clinic, and homecare settings, along with examination of formulation and route-of-administration constraints that affect adherence and patient experience. Supply-chain implications were assessed through scenario analysis that considered tariff impacts, cross-border manufacturing dependencies, and mitigation strategies such as near-shoring and redundant sourcing. Throughout the process, findings were validated through follow-up consultations with key opinion leaders and clinical program managers to ensure that recommendations are practical, clinically relevant, and aligned with current regulatory and payer expectations. This methodology prioritizes rigor, stakeholder relevance, and applicability to real-world decision-making.

A strategic synthesis highlighting the conditions and collaborative actions required to convert therapeutic innovation into sustainable improvements in PFIC patient outcomes

The PFIC treatment landscape is at an inflection point driven by scientific advances, evolving care models, and shifting economic constraints. Targeted pharmacotherapies that modulate bile acid handling, improvements in clinical networks for multidisciplinary care, and adaptive regulatory pathways collectively create an opportunity to improve outcomes for patients facing progressive cholestatic liver disease. Yet realizing these benefits requires coordinated action: robust evidence generation that speaks to regulators and payers, supply-chain strategies that mitigate external risks, and targeted commercialization plans that reflect the nuances of end-user needs and regional healthcare systems.

Stakeholders who align clinical development with pragmatic operational readiness and payer-centered value demonstration will be best positioned to translate therapeutic potential into measurable patient benefit. Equally important is the cultivation of partnerships across manufacturers, specialty clinics, transplant centers, and patient advocacy networks to ensure that access pathways are equitable and sustainable. If these elements are addressed in concert, the community can move toward earlier intervention, reduced morbidity, and improved long-term outcomes for individuals living with PFIC.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Phase iii trial data on odevixibat demonstrating significant pruritus reduction and improved bile acid profiles in PFIC patients
• 5.2. Development of adeno-associated virus gene therapies targeting ABCB11 mutations for durable restoration of bile secretion in PFIC type 2
• 5.3. Advancements in FXR agonists pipeline beyond obeticholic acid for enhanced cholestasis control in pediatric PFIC cohorts
• 5.4. Integration of liquid biopsy biomarkers for early detection and monitoring of disease progression in PFIC clinical practice
• 5.5. Cost-effectiveness analyses of emerging PFIC treatments highlighting long-term healthcare resource utilization and budget impact
• 5.6. Real-world evidence studies assessing quality-of-life improvements and adherence patterns in PFIC patients treated with ileal bile acid transport inhibitors
• 5.7. Collaborative registries leveraging digital health platforms to standardize PFIC phenotyping and accelerate patient recruitment for rare disease trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Treatment Type

• 8.1. Pharmacotherapy
  • 8.1.1. Antibiotics
  • 8.1.2. Bile Acid Sequestrants
    • 8.1.2.1. Cholestyramine
    • 8.1.2.2. Colesevelam
  • 8.1.3. Ibat Inhibitors
    • 8.1.3.1. Maralixibat
    • 8.1.3.2. Odevixibat
  • 8.1.4. Rifampicin
  • 8.1.5. Ursodeoxycholic Acid
• 8.2. Supportive Care
  • 8.2.1. Nutritional Support
  • 8.2.2. Symptom Management
• 8.3. Surgical Interventions
  • 8.3.1. Biliary Diversion
  • 8.3.2. Liver Transplantation

9. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Class

• 9.1. Antibiotics
• 9.2. Bile Acid Sequestrants
  • 9.2.1. Cholestyramine
  • 9.2.2. Colesevelam
• 9.3. Ibat Inhibitors
  • 9.3.1. Maralixibat
  • 9.3.2. Odevixibat
• 9.4. Ursodeoxycholic Acid

10. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End User

• 10.1. Homecare
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy

12. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Route Of Administration

• 12.1. Intravenous
• 12.2. Oral

13. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Patient Age Group

• 13.1. Adolescents
• 13.2. Adults
• 13.3. Children

14. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Pfic Type

• 14.1. Type I
• 14.2. Type II
• 14.3. Type III

15. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. Albireo Pharma, Inc.
  • 18.3.2. Mirum Pharmaceuticals, Inc.
  • 18.3.3. Teva Pharmaceutical Industries Ltd.
  • 18.3.4. AbbVie, Inc.
  • 18.3.5. Glenmark Pharmaceuticals Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION